drugset / Trial / NCT05465135

The Effect of Dihydroartemisinin in PCOS

NCT05465135

Phase 4 Completed 19 enrolled Shanghai Zhongshan Hospital
NaSingle-groupOpen-labelTreatment

Summary

Artemisinin has been widely used as a first-line antimalarial drug in routine clinical practice. In recent years, it has been reported that Artemisinin also has some significant anti-inflammatory, anti-tumor and immune-modulating effects. The investigators' previous studies discovered that Artemisinin dramatically reduced serum androgen levels and improved poly-cystic ovary syndrome(PCOS) in animals. Preliminary study by the investigators found that artemisinin derivatives are capable of reducing both androgen levels and improving insulin resistance, two clinical characteristics of PCOS. Thus artemisinin derivatives has the potential effect to alleviate PCOS symptoms. The current study aims to investigate the effect of artemisinin on improving PCOS and serum androgen levels in PCOS subjects.

Timeline

Start
2022-07-01
Primary completion
2023-03-23
Completion
2023-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject ARTENIMOL Small molecule 40 mg